about
Dendritic cell-based cancer immunotherapy for colorectal cancerAntimitotic drugs in the treatment of cancerThe Role of Indoleamine 2, 3-Dioxygenase in Immune Suppression and AutoimmunityDendritic cells: arbiters of immunity and immunological toleranceIn situ vaccination with CD204 gene-silenced dendritic cell, not unmodified dendritic cell, enhances radiation therapy of prostate cancerTherapeutic cancer vaccines and combination immunotherapies involving vaccinationThe adjuvanticity of an O. volvulus-derived rOv-ASP-1 protein in mice using sequential vaccinations and in non-human primatesMeta-analysis of clinical data using human meiotic genes identifies a novel cohort of highly restricted cancer-specific marker genes.Aptamer-targeted antigen delivery.Development of immune-specific interaction potentials and their application in the multi-agent-system VaccImm.DC-STAMP knock-down deregulates cytokine production and T-cell stimulatory capacity of LPS-matured dendritic cells.Dendritic cell immunotherapy in uterine cancer.A novel minigene scaffold for therapeutic cancer vaccinesThe p50 subunit of NF-κB orchestrates dendritic cell lifespan and activation of adaptive immunity.The immune response to tumors as a tool toward immunotherapy.VaccImm: simulating peptide vaccination in cancer therapy.Fucoidan can function as an adjuvant in vivo to enhance dendritic cell maturation and function and promote antigen-specific T cell immune responses.Integrated NY-ESO-1 antibody and CD8+ T-cell responses correlate with clinical benefit in advanced melanoma patients treated with ipilimumabTargeting the immunoregulator SRA/CD204 potentiates specific dendritic cell vaccine-induced T-cell response and antitumor immunityAptamers: new arrows to target dendritic cells.Antigen-specific CD4 T-cell help rescues exhausted CD8 T cells during chronic viral infection.Exploiting the interplay between innate and adaptive immunity to improve immunotherapeutic strategies for Epstein-Barr-virus-driven disordersMechanisms of dendritic cell trafficking across the blood-brain barrier.Genetic targeting of the active transcription factor XBP1s to dendritic cells potentiates vaccine-induced prophylactic and therapeutic antitumor immunity.Combined Tbet and IL12 gene therapy elicits and recruits superior antitumor immunity in vivo.Treatment with targeted vesicular stomatitis virus generates therapeutic multifunctional anti-tumor memory CD4 T cells.Immunotherapy using dendritic cells against multiple myeloma: how to improve?Loss of Gadkin Affects Dendritic Cell Migration In VitroA single nucleotide polymorphism of the cholecystokinin-B receptor predicts risk for pancreatic cancer.Reprogramming Immune Response With Capsid-Optimized AAV6 Vectors for Immunotherapy of CancerHigh-efficiency transduction of human monocyte-derived dendritic cells by capsid-modified recombinant AAV2 vectors.Regulation of memory CD4 T-cell pool size and function by natural killer T cells in vivo.Trial watch: Dendritic cell-based interventions for cancer therapyCooperativity of adaptive and innate immunity: implications for cancer therapy.Combination OX40 agonism/CTLA-4 blockade with HER2 vaccination reverses T-cell anergy and promotes survival in tumor-bearing mice.Preventive evolutionary medicine of cancersHigh-density sub-100-nm peptide-gold nanoparticle complexes improve vaccine presentation by dendritic cells in vitroGenetic Immunization With In Vivo Dendritic Cell-targeting Liposomal DNA Vaccine Carrier Induces Long-lasting Antitumor Immune Response.Magnetic drug targeting reduces the chemotherapeutic burden on circulating leukocytes.Anticancer DNA vaccine based on human telomerase reverse transcriptase generates a strong and specific T cell immune response.
P2860
Q26751339-D0A41628-4021-4F83-9A91-B43EC601FABFQ26777317-12B366D5-CF8E-43D8-BF2C-2532750E4A74Q26785900-F7AD9E01-C23B-44AA-9AA2-996B692E66BEQ27001626-2A3E3118-EF52-489F-92E4-926BBD0C64A4Q28390899-057FBDD3-20F7-4857-A15A-104FC1768F57Q28397609-2462A12E-589B-4F6A-9B66-D8D82D99F848Q28729899-FB31B41A-03A3-4BFF-9CA2-CB94ACEFDDFEQ30558949-CAC5ED4A-B7ED-45F4-96D1-BD11E197130BQ33870736-890D4085-A34A-4E3A-B520-2A246B617F66Q33999339-41AE8079-EB1A-43F7-9150-BC16AD2F1B13Q34041998-E2AED59C-0E4B-47B4-88BF-BC10A56C1270Q34291122-AF4E26CA-1D80-42EC-AA24-69218BC90A69Q34418540-C8A4A0BE-E919-4AD7-9CEC-74729C7C1139Q34438046-72A6C1A0-2580-4D75-A4A0-F065DC93B79AQ34634545-B3FAA243-78A9-4F93-A662-065BE5452D12Q34668228-613BA8FF-9204-452A-A044-35AA9E57A95DQ35183887-30C5D913-511B-4E01-89EF-977C10D1F47CQ35289145-0D2FACB2-BCD1-4EB7-B816-BD86E75CF957Q35543558-74876017-5F68-4744-92AF-7FE95977BC34Q35624065-9BCB88E0-70EF-41DF-B5A0-3262E5D56DC7Q35641516-D0890C1A-E3BE-4964-83E7-C70139586A8AQ35738744-40B0E5FC-7710-4A11-9636-51B4B738D3BFQ35748581-1D8E9990-D5D4-43C0-97CB-A2586B038501Q35750026-96B2B957-2551-474C-B227-AB6BCB52D8D8Q35802152-D1EFFE78-EC0B-438F-9FCB-4B67E19C063AQ35840314-F1341DE1-4955-44EA-8B5A-8A2B2B261145Q35852574-95DB178C-37E9-4518-B229-F37A7074A525Q35856882-CAC9387A-E8F6-4BB6-83D5-A40ED6529339Q35911669-2A841CC6-3E0E-4B19-98C9-0618C50D8A8BQ35949356-E2C9CDAD-9867-445E-B379-B90F3FB885DAQ35973549-761D05BB-B56A-4B44-BBC0-088C89C1BB2DQ36342679-CCD6AB77-E65C-4CF7-9681-6902D012422CQ36388529-0BD75574-30C3-4196-AB10-97E267CB8622Q36429508-6E806266-BFA3-42FB-8C37-160F55308DFBQ36498243-AA336CD4-7AEE-4102-AAAF-0B4F5B06DF14Q36595780-D625619B-53B0-4D18-B02E-9F158EA4CC45Q36630822-3B2B5208-4F94-40CA-ABE6-C85A8B716CC6Q36756884-D4E5AE8B-2BE4-4258-ADB3-A67658D6DEA3Q36820444-86D77332-22EC-4D6D-9BF8-85451902D1E0Q36821063-A71603DF-2D40-4CEC-908D-41E60AE40350
P2860
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on February 2011
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Recent developments in cancer vaccines
@en
Recent developments in cancer vaccines.
@nl
type
label
Recent developments in cancer vaccines
@en
Recent developments in cancer vaccines.
@nl
prefLabel
Recent developments in cancer vaccines
@en
Recent developments in cancer vaccines.
@nl
P2860
P356
P1476
Recent developments in cancer vaccines
@en
P2093
Karolina Palucka
P2860
P304
P356
10.4049/JIMMUNOL.0902539
P407
P577
2011-02-01T00:00:00Z